- Home
- IBCP vs IOVA Comparison
IBCP vs IOVA Comparison
Compare IBCP & IOVA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IBCP
- IOVA
- Stock Information
- Founded
- IBCP 1864
- IOVA 2007
- Country
- IBCP United States
- IOVA United States
- Employees
- IBCP N/A
- IOVA N/A
- Industry
- IBCP Major Banks
- IOVA Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- IBCP Finance
- IOVA Health Care
- Exchange
- IBCP Nasdaq
- IOVA Nasdaq
- Market Cap
- IBCP 682.2M
- IOVA 975.1M
- IPO Year
- IBCP N/A
- IOVA N/A
- Fundamental
- Price
- IBCP $31.13
- IOVA $2.30
- Analyst Decision
- IBCP Hold
- IOVA Buy
- Analyst Count
- IBCP 3
- IOVA 11
- Target Price
- IBCP $36.00
- IOVA $11.90
- AVG Volume (30 Days)
- IBCP 80.8K
- IOVA 10.8M
- Earning Date
- IBCP 10-23-2025
- IOVA 11-06-2025
- Dividend Yield
- IBCP 3.29%
- IOVA N/A
- EPS Growth
- IBCP N/A
- IOVA N/A
- EPS
- IBCP 3.06
- IOVA N/A
- Revenue
- IBCP $217,457,000.00
- IOVA $241,525,000.00
- Revenue This Year
- IBCP N/A
- IOVA $67.40
- Revenue Next Year
- IBCP $5.56
- IOVA $56.32
- P/E Ratio
- IBCP $10.32
- IOVA N/A
- Revenue Growth
- IBCP 2.56
- IOVA 636.99
- 52 Week Low
- IBCP $26.75
- IOVA $1.64
- 52 Week High
- IBCP $40.32
- IOVA $12.51
- Technical
- Relative Strength Index (RSI)
- IBCP 38.65
- IOVA 50.67
- Support Level
- IBCP $31.01
- IOVA N/A
- Resistance Level
- IBCP $32.39
- IOVA $2.46
- Average True Range (ATR)
- IBCP 0.63
- IOVA 0.14
- MACD
- IBCP -0.18
- IOVA -0.09
- Stochastic Oscillator
- IBCP 6.61
- IOVA 92.00
About IBCP Independent Bank Corporation
Independent Bank Corp (Ionia MI) operates as a commercial bank. It offers a broad range of banking services to individuals and businesses, including checking and savings accounts, commercial lending, direct and indirect consumer financing, mortgage lending, and safe deposit box services. It also provides internet and mobile banking capabilities to its customers.
About IOVA Iovance Biotherapeutics Inc.
Iovance Biotherapeutics Inc is a clinical-stage biopharmaceutical company, pioneering a transformational approach to treating cancer by harnessing the human immune system's ability to recognize and destroy diverse cancer cells using therapies personalized for each patient. The company is preparing for potential U.S. regulatory approvals and commercialization of the first autologous T-cell therapy to address a solid tumor cancer. its objective is to be the leader in innovating, developing, and delivering tumor-infiltrating lymphocyte, or TIL, therapies for patients with solid tumor cancers.